| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| No Relationships to Disclose |
|
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| Company: Merck Serono |
| Recipient: An Immediate Family Member |
| Company: Boehringer Ingelheim |
| Recipient: An Immediate Family Member |
| Company: Novartis |
| Recipient: An Immediate Family Member |
| Company: BioNtech |
| Recipient: An Immediate Family Member |
| Company: Bristol-Myers Squibb/Medarex |
| Recipient: An Immediate Family Member |
| Company: Merus NV |
| Recipient: An Immediate Family Member |
| Company: Neogene Therapeutics |
| Recipient: An Immediate Family Member |
| Company: Tempus |
| Recipient: An Immediate Family Member |
| Company: Ability Pharma |
| Recipient: An Immediate Family Member |
| Company: Agenus |
| Recipient: An Immediate Family Member |
| Company: Alligator Biosciences |
| Recipient: An Immediate Family Member |
| Company: Astellas |
| Recipient: An Immediate Family Member |
| Company: Astellas |
| Recipient: An Immediate Family Member |
| Company: Arcus |
| Recipient: An Immediate Family Member |
| Company: Fibrogen |
| Recipient: An Immediate Family Member |
| Company: Moma Therapeutics |
| Recipient: An Immediate Family Member |
| Company: Regeneron |
| Recipient: An Immediate Family Member |
| Company: Revolution Medicines |
| Recipient: An Immediate Family Member |
| Company: Syros |
| Recipient: An Immediate Family Member |
| Company: Tango |
| Recipient: An Immediate Family Member |
| Company: Ipsen |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
| Company: Yiviva |
| Recipient: You |
| Company: Roche/Genentech |
| Recipient: You |
| Company: Autem |
| Recipient: You |
| Company: Berry Genomics |
| Recipient: You |
| Company: Vector Health |
| Recipient: You |
| Company: Servier |
| Recipient: You |
| Company: J-Pharma |
| Recipient: You |
| Company: Abbvie |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: AstraZeneca |
| Recipient: Your Institution |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: BioNtech |
| Recipient: Your Institution |
| Company: Genentech/Roche |
| Recipient: Your Institution |
| Company: Helsinn |
| Recipient: Your Institution |
| Company: Yiviva |
| Recipient: Your Institution |
| Company: Elicio Therapeutics |
| Recipient: Your Institution |
| Company: Agenus |
| Recipient: Your Institution |
| Company: Parker Institute for Cancer Immunotherapy |
| Recipient: Your Institution |
| Company: Pertzye |
| Recipient: Your Institution |
| Company: Arcus |
| Recipient: Your Institution |
| Company: Abbvie |
| Recipient: Your Institution |
| Company: Atara |
| Recipient: Your Institution |
| Company: Beigene |
| Recipient: Your Institution |
| Company: Digestive Care |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| No Relationships to Disclose |
|
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| No Relationships to Disclose |
|
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| not answered |
|
|
| (OPTIONAL) Open Payments Link |
| not answered |
|
|